The company's success is largely attributed to the popularity of its weight-loss medications, which have seen significant sales growth in recent months.
Eli Lilly has reported a surge in profits due to high demand for its weight-loss drugs, according to the company's latest financial update.
The US drugmaker is set to raise its revenue outlook for the second time in three months, indicating a strong performance in the pharmaceutical sector.
The company's success is largely attributed to the popularity of its weight-loss medications, which have seen significant sales growth in recent months.
The increased revenue outlook is a positive sign for the company, but the long-term sustainability of this growth is not yet confirmed, and further developments are awaited.
